Ash A Alizadeh
Overview
Explore the profile of Ash A Alizadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
26849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
Blood
. 2025 Jan;
PMID: 39869833
Most diffuse large B-cell lymphoma (DLBCL) patients treated with immunotherapies such as bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the...
2.
Schroers-Martin J, Alizadeh A
JCO Oncol Pract
. 2024 Nov;
20(11):1491-1499.
PMID: 39531844
Liquid biopsy techniques using cell-free DNA (cfDNA) play an increasingly important role in the characterization and surveillance of solid tumors. For blood cancers, molecular response assessment techniques using circulating malignant...
3.
Hamilton M, Alizadeh A
Transplant Cell Ther
. 2024 Sep;
30(10):936-938.
PMID: 39326982
No abstract available.
4.
Murciano-Goroff Y, Hui A, Araujo Filho J, Hamilton E, Chabon J, Moding E, et al.
JCO Precis Oncol
. 2024 Sep;
8:e2400216.
PMID: 39231375
Purpose: Small cell lung cancer (SCLC) is characterized by rapid progression after platinum resistance. Circulating tumor (ctDNA) dynamics early in treatment may help determine platinum sensitivity. Materials And Methods: Serial...
5.
Hamilton M, Miklos D, Alizadeh A
N Engl J Med
. 2024 Sep;
391(9):870-871.
PMID: 39231355
No abstract available.
6.
Jun S, Shukla N, Durm G, Hui A, Cao S, Ganti A, et al.
J Thorac Oncol
. 2024 Jul;
19(10):1427-1437.
PMID: 38971369
Introduction: The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the...
7.
Goldstein J, Alizadeh A
N Engl J Med
. 2024 Jun;
390(23):2209-2211.
PMID: 38899699
No abstract available.
8.
Hamilton M, Sugio T, Noordenbos T, Shi S, Bulterys P, Liu C, et al.
N Engl J Med
. 2024 Jun;
390(22):2047-2060.
PMID: 38865660
Background: The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. Methods: We...
9.
Azad T, Nanjo S, Jin M, Chabon J, Kurtz D, Chaudhuri A, et al.
NPJ Precis Oncol
. 2024 May;
8(1):121.
PMID: 38806586
Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81...
10.
Hamilton M, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, et al.
Blood Adv
. 2024 Mar;
8(12):3314-3326.
PMID: 38498731
Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas (BCLs). CAR19 cell expansion is necessary for CAR19 function but is also associated...